Dominari (NASDAQ:DOMH) Cut to Sell at Wall Street Zen

Wall Street Zen cut shares of Dominari (NASDAQ:DOMH) from a hold rating to a sell rating in a research report sent to investors on Saturday morning.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dominari in a research report on Monday, July 6th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Dominari has a consensus rating of “Sell”.

Dominari Price Performance

NASDAQ DOMH opened at $2.59 on Friday. Dominari has a fifty-two week low of $2.19 and a fifty-two week high of $8.40. The stock’s 50-day moving average is $2.86 and its two-hundred day moving average is $3.10. The firm has a market cap of $62.78 million, a P/E ratio of -0.48 and a beta of 0.87.

Dominari (NASDAQ:DOMH) last released its quarterly earnings results on Monday, August 10th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.34) by $0.13. Dominari had a negative return on equity of 235.37% and a negative net margin of 51.61%.The company had revenue of $16.79 million during the quarter, compared to the consensus estimate of $16.79 million.

Institutional Investors Weigh In On Dominari

A number of hedge funds have recently bought and sold shares of DOMH. PFG Investments LLC grew its position in shares of Dominari by 36.3% in the first quarter. PFG Investments LLC now owns 14,475 shares of the company’s stock valued at $47,000 after purchasing an additional 3,855 shares during the last quarter. NewEdge Advisors LLC acquired a new position in shares of Dominari during the 4th quarter worth about $50,000. Price T Rowe Associates Inc. MD bought a new stake in Dominari during the 4th quarter valued at approximately $96,000. Oxford Asset Management LLP bought a new stake in Dominari during the 4th quarter valued at approximately $120,000. Finally, Jane Street Group LLC acquired a new stake in Dominari in the 2nd quarter valued at approximately $158,000. 42.48% of the stock is currently owned by institutional investors.

Dominari Company Profile

Dominari Holdings Inc, a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2.